

- Combination antiretroviral therapy (cART), protease inhibitors (*Cont.*):
 molecular structure of, 1276f
 resistance to, 1278, 1280f
 resistance testing for, 1248
 reverse transcriptase inhibitors, **1274–1275t**
 action of, 1273, 1278
 adverse effects of, 318, 1273, 1278
 drug interactions of, 798
 for HIV infection, 1273, 1274–1275t, 1278
 molecular structure of, 1276f
 resistance to, 1279f
 selection of initial drugs, 1282, 1282t
- Combined pituitary hormone deficiency (CPHD), 2325t
- Comedones, 351
- Commensals, 86e-1
- COMMIT (Community Intervention Trial for Smoking Cessation), 476
- Common carotid artery, 2574
- Common cold, 225–226
 adenovirus, 1208
 clinical features of, 1202t
 coronavirus, 1204
 HMPV, 1206
 HRSV, 1205
 parainfluenza virus, 1207
 rhinovirus, 1203
 treatment of, 1203
- Common variable immunodeficiency (CVID), 2111
- Commonwealth Serum Laboratories, 2742
- Commotio cordis, 289e-3
- Communication
 of bad news, 57–58, 57t
 racial/ethnic factors in, 16e-3–4, 16e-4f
- Community-acquired pneumonia. *See* Pneumonia, community-acquired
- Community Intervention Trial for Smoking Cessation (COMMIT), 476
- Comparative genomic hybridization (CGH), 83e-3, 83e-3t
- Comparative genomics, 426
- Compensatory enlargement, 291e-4
- COMP gene mutations, 2512
- Complementary and alternative medicine, **14e-1**
 for asthma, 1678
 for back pain, 120
 cancer treatment, 473
 definitions and scope of, 14e-1–2
 herbal medicines. *See* Herbal medicines/supplements
 information sources on, 14e-4, 14e-4t
 licensure and accreditation in, 14e-2
 patterns of use of, 14e-2
 vitamin and mineral supplements. *See* Dietary supplements
- Complement factor H, 205, 1832
- Complement system
 deficiencies of, 372e-28, 372e-29t, 2106–2107
 definition of, 372e-1
 in HIV infection, 1244
 innate immune system and, 372e-4t, 372e-9
 pathways of, 372e-9, 372e-16f
 in shock, 1746
- Complete blood count (CBC), 393, 394t
- Complete heart block, 278e-4f, 278e-10f, 1472. *See also* Atrioventricular (AV) conduction block
- Complete response, to chemotherapy, 103e-5
- Complex IV (COX), 94e-3
- Complex partial status epilepticus, 2607
- Complex regional pain syndrome (CRPS)
 clinical features of, 90, 2246, 2644
 treatment of, 2644
 type I, 90, 2246, 2643
 type II, 90, 2643–2644
- Complex sleep apnea, 1727
- Complex systems, 87e-1
- Composite tissue transplantation, 928
- Compound heterozygote, 435
- Comprehension, assessment of, 177
- Compression of morbidity, 94e-1
- Compression stockings
 for chronic venous disease, 1652
 for DVT prophylaxis, 1634
 for lymphedema, 1655
 for stasis dermatitis/ulceration, 344t, 346
- Compression ultrasonography, of leg veins, 613
- Computed tomography (CT)
 adrenal, 1619
 in adrenocortical carcinoma, 2323f
 in appendicitis, 1988, 1988f
 in ARDS, 308e-10f, 1738f
 in asbestosis, 308e-15f
 in *Aspergillus* infections, 1348
 in bile duct evaluation, 2085t
 in bone mass measurement, 2493
 in bronchiectasis, 308e-12f
 in CAH, 2328f
 in cardiac disease
 angiography. *See* Computed tomography (CT) angiography (CTA)
 CAD, 270e-10, 270e-11f, 270e-12, 270e-12f, 270e-13f, 1585
 for calcium scoring, 270e-4, 270e-7f, 270e-11f
 contrast agents in, 270e-9
 cor pulmonale, 1506
 infective endocarditis, 270e-24, 270e-25f
- chest, **308e-2**
 air bronchograms, 308e-11f
 normal, 308e-2f
 parenchymal loss, 308e-5–6f
 volume loss, 308e-3–4f
 in cirrhosis, 286, 286f
 in Cushing's syndrome, 2317, 2317f
 in diffuse axonal injury, 457e-2f
 in eosinophilic granulomatosis with polyangiitis, 1685
 in granulomatosis with polyangiitis, 2183f
 halo sign on, 1348
 in hearing loss evaluation, 223
 helical, 1664, 1665f
 in hemoptysis, 246–247
 high-resolution, 1664
 in hypersensitivity pneumonitis, 1682, 1682f
 in interstitial lung diseases, 308e-7–9f, 1710, 1710f
 in intestinal obstruction, 1984, 1984f
 in lung cancer diagnosis, 308e-15–16f
 in lung cancer screening, 509–510, 510t
 in lung cancer staging, 513
 in mineralocorticoid excess, 2319
 multidetector, 1664–1666
 in musculoskeletal disease evaluation, 2224–2225, 2224t, 2225f
 in nephrolithiasis, 1869f
 in NETs, 572, 572f
 in neurologic disease. *See also* Neuroimaging, CT
 adrenoleukodystrophy, 441e-41f
 anterior dens dislocation, 441e-31f
 cavernous malformation, 440e-7f
 cerebral contusion, 457e-1f
 CNS vasculitis, 441e-19f
 coma, 1775
 epidural hematoma, 441e-31f, 457e-3f
 Huntington's disease, 441e-23f
 intracerebral hemorrhage, 2584
 Jefferson fracture, 441e-32f
 lacunar infarction, 441e-17f
 ligament injury, 441e-33f
 neurologic critical illness, 1779
 seizures, 2550
 stroke, 2580, 2581f
 subarachnoid hemorrhage, 1786, 1786f
 subdural hematoma, 457e-3f, 457e-4
 superior sagittal sinus thrombosis, 441e-20f
 vertebral fractures, 441e-31f, 441e-33f, 441e-34f
 viral encephalitis, 895
 in osteomyelitis, 842, 842f
 in pancreatic cancer diagnosis, 555, 555f
 in pancreatic disease evaluation, 2087t, 2088–2089
- in pancreatitis, 2094–2095, 2094f, 2095f, 2099–2100, 2100f
 in pneumothorax, 308e-14f
 in pulmonary arteriovenous malformation, 308e-17f
 in pulmonary embolism, 308e-17f, 1633, 1633f
 in pulmonary hypertension, 308e-18f, 1656
 in respiratory disease evaluation, 1663, 1664–1666, 1664f, 1665f
 in sarcoidosis, 2206, 2206f, 2208f, 2209f
 of temporal bone, 220, 223
 in tracheomalacia, 308e-13f
 in urinary tract obstruction, 1873
- Computed tomography (CT) angiography (CTA)
 in cerebral artery aneurysm, 440e-2f
 coronary
 in anomalous right coronary artery, 271e-4f
 in aortic aneurysm, 1640f
 in aortic stenosis, 270e-17
 in CAD evaluation, 270e-5f, 271e-2f, 1594–1595, 1594f
 in chest pain evaluation, 102, 270e-14, 270e-14f, 270e-15, 270e-16f
 contrast agents in, 270e-9
 in coronary aneurysm, 271e-4f
 in murmur evaluation, 51e-8
 principles of, 270e-4
 neurologic, 440e-1
 in cerebral artery aneurysm, 440e-2f
 in cerebral artery occlusion, 440e-3f
 in small-vessel stroke, 2567f
 in subarachnoid hemorrhage, 1786f
 in pulmonary hypertension, 1656
 of renal arteries, 1628, 1628t, 1630f
- Computed tomography (CT) cisternography, 440e-2
- Computed tomography (CT) colonography, 481t, 482
- Computed tomography (CT) myelography, 440e-2, 440e-9–10
- Computerized physician order entry (CPOE), 12e-2
- COMT (catechol-O-methyltransferase) inhibitors, 2615, 2616t
- Concentration gradients, 332e-6
- Concussion, **457e-1**
 clinical features of, 471e-3
 definition of, 457e-1
 mechanics of, 457e-1
 sports-related, 457e-4
 in war veterans, 471e-2–3, 471e-3t
- Condoms, 1009, 1285
- Conduction aphasia, 177t, 178
- Condyloma acuminata (anogenital warts)
 anal cancer and, 544
 clinical features of, 76e-11f, 1198, 1199f
 in HIV infection, 1263
 treatment of, 215e-4t, 351, 1200–1201, 1201f
- Condylomata lata, 25e-5f, 76e-10f, 1259
- Cone(s), 195, 197
- Cone-nose bug bite, 2750
- Cone snail envenomation, 2740
- Confabulation, 182
- Confidentiality, in patient-physician relationship, 17e-1
- Conflicts of interest, 17e-3–4
- Confocal fluorescent laser microscopy (CFM), 1668
- Confusion, 166, 1771. *See also* Delirium
- Confusion Assessment Method, 167, 167t
- Conga ant, 2749
- Congeniters, 2723
- Congenital absence of vagina, 2357
- Congenital adrenal hyperplasia (CAH), **2327**
 clinical features of
 ambiguous genitalia, 437, 2355
 cutaneous, 356t, 2355
 hirsutism, 331, 2355
 hypokalemia, 306
 precocious puberty, 2362
 sex differences in, 2328
 diagnosis of, 332–333, 2328, 2328f
 etiology of, 2355